NCT02762721 is a clinical trial in Intrahepatic Cholangiocarcinoma, sponsored by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA).

What condition does NCT02762721 study?

NCT02762721 studies Intrahepatic Cholangiocarcinoma, Mixed Hepatocellular Cholangiocarcinoma, Cholangiocarcinoma.

Is NCT02762721 still recruiting?

NCT02762721 is currently completed. Last updated 8 June 2017.

Last reviewed 2017-06-08 · How we verify

NCT02762721

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples

Completed Last updated 8 June 2017

What this trial tests

trial in Intrahepatic Cholangiocarcinoma in 131 participants. Completed in 6 April 2017.

Timeline

6 June 2016

Primary endpoint
6 April 2017

6 April 2017

Quick facts

Lead sponsor	ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Status	Completed
Study type	OBSERVATIONAL
Enrollment	131
Start date	6 June 2016
Primary completion	6 April 2017
Estimated completion	6 April 2017
Sites	6 locations across Italy, United States

Conditions studied

Intrahepatic Cholangiocarcinoma — all drugs for Intrahepatic Cholangiocarcinoma →
Mixed Hepatocellular Cholangiocarcinoma — all drugs for Mixed Hepatocellular Cholangiocarcinoma →
Cholangiocarcinoma — all drugs for Cholangiocarcinoma →

Sponsor

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) — full company profile →

Who can join

18 and older, any sex, with Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular Cholangiocarcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to estimate the frequency of FGFR2 fusions in archived intrahepatic cholangiocarcinoma (iCCA) or mixed hepatocellular-cholangiocarcinoma (HCC-CCA) tumor samples

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Intrahepatic Cholangiocarcinoma

Currently open trials in the same condition.

NCT06990659 — Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC) · NA · recruiting
NCT06910722 — Liver Transplantation for Locally Advanced Intrahepatic Cholangiocarcinoma After SIRT and Chemotherapy · NA · recruiting
NCT07169734 — A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors · Phase 1, PHASE2 · recruiting
NCT06664021 — Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperativ · Phase 2 · recruiting
NCT06505486 — GEMOX-HAIC Plus GEM-SYS in Combination With Lenvatinib and PD-1 Inhibitor for Large Unresectable ICC · recruiting

Other ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) trials

Trials by the same sponsor.

NCT03162536 — A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK- · Phase 1, PHASE2 · active not recruiting
NCT03094832 — Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK · Phase 1, PHASE2 · terminated
NCT02761694 — Vevorisertib (ARQ 751) as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / · Phase 1 · terminated
NCT02476955 — Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole · Phase 1 · terminated
NCT01178411 — An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols · Phase 1, PHASE2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02762721 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Last refreshed: 8 June 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02762721.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing